You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

CLINICAL TRIALS PROFILE FOR DILANTIN-125

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for DILANTIN-125

Subscribe to access the full database, or Subscribe
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00005951 ↗	Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma	Completed	National Cancer Institute (NCI)	Phase 1	2000-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of irinotecan plus temozolomide in treating patients who have recurrent primary malignant glioma.
NCT00005951 ↗	Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma	Completed	Duke University	Phase 1	2000-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of irinotecan plus temozolomide in treating patients who have recurrent primary malignant glioma.
NCT00040469 ↗	Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies	Terminated	Center for Cell and Gene Therapy, Baylor College of Medicine	Phase 2	2000-08-01	The major goal of this study is to determine the risks and benefits of bone marrow transplants in patients with severe thalassemia or sickle cell disease. Participation in this project will be for two years.
NCT00040469 ↗	Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies	Terminated	Texas Children's Hospital	Phase 2	2000-08-01	The major goal of this study is to determine the risks and benefits of bone marrow transplants in patients with severe thalassemia or sickle cell disease. Participation in this project will be for two years.
NCT00040469 ↗	Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies	Terminated	The Methodist Hospital Research Institute	Phase 2	2000-08-01	The major goal of this study is to determine the risks and benefits of bone marrow transplants in patients with severe thalassemia or sickle cell disease. Participation in this project will be for two years.
NCT00040469 ↗	Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies	Terminated	The Methodist Hospital System	Phase 2	2000-08-01	The major goal of this study is to determine the risks and benefits of bone marrow transplants in patients with severe thalassemia or sickle cell disease. Participation in this project will be for two years.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for DILANTIN-125

Condition Name

Chart
Table

Condition Name for DILANTIN-125
Intervention	Trials
Gliosarcoma	3
Healthy	3
Leukemia	3
Traumatic Brain Injury	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for DILANTIN-125
Intervention	Trials
Seizures	5
Glioma	4
Brain Injuries, Traumatic	3
Brain Injuries	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for DILANTIN-125

Trials by Country

Map
Table

Trials by Country for DILANTIN-125
Location	Trials
United States	22
Canada	1
Singapore	1
Korea, Republic of	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for DILANTIN-125
Location	Trials
Texas	3
North Carolina	3
Ohio	3
Pennsylvania	2
New York	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for DILANTIN-125

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for DILANTIN-125
Clinical Trial Phase	Trials
Phase 4	6
Phase 3	2
Phase 2	4
[disabled in preview]	10
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for DILANTIN-125
Clinical Trial Phase	Trials
Completed	13
Terminated	8
Active, not recruiting	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for DILANTIN-125

Sponsor Name

Chart
Table

Sponsor Name for DILANTIN-125
Sponsor	Trials
National Cancer Institute (NCI)	3
Duke University	3
Baylor College of Medicine	3
[disabled in preview]	6
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for DILANTIN-125
Sponsor	Trials
Other	35
Industry	10
NIH	4
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.